Kartogenin |
| Catalog No.GC15057 |
La kartogénine (KGN) est un inducteur de différenciation des cellules souches mésenchymateuses humaines en chondrocytes, avec une CE50 de 100 nM.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 4727-31-5
Sample solution is provided at 25 µL, 10mM.
;)
_1-7.$$$37316672@70.jpg');)
;)
;)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
;)
;)
;)
_1124-1138.$$$35908550@30.jpg');)
_766-780.$$$37100057@30.jpg');)
_418-432.$$$36893736@30.jpg');)
_240-255.$$$35108512@29.jpg');)
_533-545.$$$36543525@28.jpg');)
_264-276.$$$36600053@22.jpg');)
_2214998.$$$@0.jpg');)
Kartogenin is a potent inducer that promoting the differentiation of multipotent mesenchymal stem cells (MSCs) into chondrocytes with EC50 value of 100 nM [1].
MSCs are a kind of stem cell that can differentiate into different cell types including chondrocytes, osteoblasts, adipocytes and myocytes.
Kartogenin (KGN) potently induced the differentiation of hMSCs into chondrocytes in a dose-dependent way [1]. In preskeletal mesenchymal cells from mice, KGN stimulated the formations of cartilage nodule and synovial joint, boosted digit cartilaginous anlaga elongation and stimulated interdigit invagination, tendon maturation and interzone compaction. KGN increased the expression of TGFβ1, which stimulated cartilage nodule formation. Also, KGN increased the phosphorylation of Smads that mediated BMP and TGFβ signaling [2].
In the acute surgical model and the chronic joint injury model, kartogenin showed chondroprotective effects. Kartogenin disrupted the interaction of filamin A and the transcription factor core-binding factor β subunit (CBFβ) and regulated the CBFβ-RUNX1 transcriptional, which then induced chondrogenesis [1]. In the dermis of BALB/C mice, KGN induced synthesis of type-I collagen and activated Smad4/smad5 signaling pathway of the TGF-β [3].
References:
[1]. Johnson K, Zhu S, Tremblay MS, et al. A stem cell-based approach to cartilage repair. Science, 2012, 336(6082): 717-721.
[2]. Decker RS, Koyama E, Enomoto-Iwamoto M, et al. Mouse limb skeletal growth and synovial joint development are coordinately enhanced by Kartogenin. Dev Biol, 2014, 395(2): 255-267.
[3]. Wang J, Zhou J, Zhang N, et al. A heterocyclic molecule kartogenin induces collagen synthesis of human dermal fibroblasts by activating the smad4/smad5 pathway. Biochem Biophys Res Commun, 2014, 450(1): 568-574.
Cell experiment: | Rabbit BMSCs or PTSCs are treated with various concentrations (1 nM to 5 μM) of kartogenin. The medium is changed every 3 days and after 2 weeks, cell proliferation is measured by population doubling time[1]. |
Animal experiment: | Rats: Then rats are divided into two groups based on the injections received: six rats are given 10 µL saline injections in each wound (wound-only group) and six rats receive 10 µL of 100 µM kartogenin solution each in the wounded areas (wound+kartogenin group). The injections are given immediately after wounding and repeated on days 2, 4, 7 and 12[1]. |
References: [1]. Zhang J, et al. Kartogenin induces cartilage-like tissue formation in tendon-bone junction. Bone Res. 2014;2. pii: 14008. | |
| Cas No. | 4727-31-5 | SDF | |
| Chemical Name | 2-[(4-phenylphenyl)carbamoyl]benzoic acid | ||
| Canonical SMILES | O=C(C1=CC=CC=C1C(O)=O)NC2=CC=C(C=C2)C3=CC=CC=C3 | ||
| Formula | C20H15NO3 | M.Wt | 317.34 |
| Solubility | ≥ 10.6mg/mL in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.1512 mL | 15.756 mL | 31.5119 mL |
| 5 mM | 0.6302 mL | 3.1512 mL | 6.3024 mL |
| 10 mM | 0.3151 mL | 1.5756 mL | 3.1512 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 3 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *